WO2004064849A1 - Produit normalisant la structure et les fonctions des organes et tissus, stimulant les reparations des lesions et possedant une activite antivirale - Google Patents

Produit normalisant la structure et les fonctions des organes et tissus, stimulant les reparations des lesions et possedant une activite antivirale Download PDF

Info

Publication number
WO2004064849A1
WO2004064849A1 PCT/EA2004/000001 EA2004000001W WO2004064849A1 WO 2004064849 A1 WO2004064849 A1 WO 2004064849A1 EA 2004000001 W EA2004000001 W EA 2004000001W WO 2004064849 A1 WO2004064849 A1 WO 2004064849A1
Authority
WO
WIPO (PCT)
Prior art keywords
days
medication
dose
mass
molecular weight
Prior art date
Application number
PCT/EA2004/000001
Other languages
English (en)
Russian (ru)
Inventor
Viktor Nikolaevich Vitvitsky
Igor Vladimirovich Ushakov
Dmitry Pavlovich Sidlyarov
Yury Dmitrievich Aprosin
Original Assignee
Zakrytoe Aktsionernoe Obschestvo 'astera'
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zakrytoe Aktsionernoe Obschestvo 'astera' filed Critical Zakrytoe Aktsionernoe Obschestvo 'astera'
Publication of WO2004064849A1 publication Critical patent/WO2004064849A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • each link must be discontinued, and then there is a joint disruption of the function of the With d ⁇ ug ⁇ y s ⁇ ny with ⁇ m ⁇ schyu izves ⁇ ny ⁇ sis ⁇ emny ⁇ ⁇ egulya ⁇ v tsel ⁇ g ⁇ ⁇ ganizma, na ⁇ ime ⁇ , g ⁇ m ⁇ n ⁇ v, m ⁇ zhn ⁇ s ⁇ imuli ⁇ va ⁇ , ingibi ⁇ va ⁇ or vyzva ⁇ sis ⁇ emnye ⁇ e ⁇ es ⁇ y ⁇ i in ⁇ ab ⁇ e s ⁇ azu ⁇ g ⁇ mn ⁇ g ⁇ ⁇ liches ⁇ va ⁇ azny ⁇ ⁇ ea ⁇ tsy, b ⁇ lshins ⁇ v ⁇ of ⁇ y ⁇ not ⁇ n ⁇ sya ⁇ sya ⁇ ⁇ a ⁇ l ⁇ gii, ⁇ uyu ⁇ y ⁇ ayu ⁇ sya ⁇ im
  • the use of the payment method is declared, the main component of the payment is the payment of the payment terms, the payment for the (application ⁇ , 93043514, 09/01/93).
  • the closest of the analogues is the medicament that stimulates the growth of the world and method of its transmission ( ⁇ , 2144366, 03.03.1998).
  • This patent describes a method for isolating nuclear ⁇ from the hairy bulbs of young living animals. The result is that this means that the product is free of charge, with constant sedimentation of up to 8 8, the main weight of the unit was only 250 milliliters.
  • the described method does not make it possible to make a profit from a number of friends with a high degree of payment and the fact that they are not allowed to use other languages.
  • P ⁇ s ⁇ avlennaya task ⁇ eshae ⁇ sya ⁇ em, ch ⁇ vesches ⁇ va isolated from m ⁇ zga, ⁇ echeni, end ⁇ inny ⁇ l ⁇ Elez and immunn ⁇ m ⁇ e ⁇ en ⁇ ny ⁇ ⁇ aney with is ⁇ lz ⁇ vaniem b ⁇ lee s ⁇ ve ⁇ shenny ⁇ me ⁇ d ⁇ v vscheleniya ⁇ bladayu ⁇ n ⁇ malizuyuschim deys ⁇ viem in ⁇ n ⁇ shenii ⁇ un ⁇ tsy ⁇ gan ⁇ v from ⁇ y ⁇ ⁇ ni ⁇ lucheny and ⁇ a ⁇ zhe s ⁇ s ⁇ bny s ⁇ imuli ⁇ va ⁇ ⁇ e ⁇ a ⁇ i ⁇ vanie ⁇ v ⁇ el ⁇ tseny ⁇ le ⁇ e ⁇ i ⁇ ⁇ gan ⁇ v, vyzvanny ⁇ ⁇ a ⁇ unfavorable external influences, such
  • the solution of the fixed task is achieved due to the fact that the separate thing is separate, which is separated from the mains of various tkane and the device is delivered.
  • the claimed disclosure provides a complete set of fractions of the United States with constant sedimentation in articles of 3 to 8 to 8, which is a little to the middle.
  • the total content of nucleic acid in the proposed product is 90% by weight or more, protein is 0.5% by weight and 5.0% by weight, and is 100% by weight.
  • S ⁇ ednie values m ⁇ le ⁇ ulya ⁇ ny ⁇ mass vesches ⁇ v, ⁇ luchenny ⁇ with is ⁇ lz ⁇ vaniem ⁇ azny ⁇ ⁇ imiches ⁇ i ⁇ ⁇ e ⁇ a ⁇ a ⁇ v and usl ⁇ vy allocation, ⁇ isanny ⁇ further ⁇ ayu ⁇ e ⁇ a ⁇ and s ⁇ s ⁇ av ⁇ imesey, ⁇ lichalis very neznachi ⁇ eln ⁇ , ch ⁇ dae ⁇ v ⁇ zm ⁇ l n ⁇ s ⁇ schi ⁇ a ⁇ , ch ⁇ all is ⁇ lz ⁇ vavshiesya us ⁇ tsedu ⁇ y allocation ⁇ P ⁇ iv ⁇ dya ⁇ ⁇ ⁇ lucheniyu ⁇ dni ⁇ and ⁇ e ⁇ same s ⁇ eds ⁇ v
  • Biological activity can be studied by examining the impact of the claimed medication when introducing normal economic incidents to people who are involved in the treatment of ill health.
  • the claimed device which contains a set of FAC fractions, which are isolated from the nucleus of mammals that is beneficial to the consumer, is beneficial to the user. With the separation of the obligatory separation and the disposal of all the cytoplasm in the process of isolation of cell nuclei with the use of the cost of the scuffling.
  • the method of use is claimed to be limited to occupational, multiple, or single injections, in general or in small form. In this case, it is diluted in a physiological solution or in the case of anesthetics, for example, in a novostain solution.
  • ⁇ ig. 1 illustrates the diagram of the intensity of the inclusion of ⁇ -leucine in the enriched by the fractions of the fractions of more bones of hearing in the absence of biomedical information after 42 studies;
  • ⁇ ig. 2 the diagram of the intensity of the inclusion of ⁇ -leucine in the enriched with fractions of the risk of taking more hearing from the brain after the study has been studied for 16 days;
  • ⁇ ig. 3 - the diagram indicates the intensity of the inclusion of 3 ⁇ -leucine in the enriched with glial cells section of the tissue of the hearing of the brain, which has been studied for 42 days;
  • ⁇ ig. 4 - the diagram shows the intensity of the inclusion of ⁇ -leucine in the enriched with glial cells section of the tissue of the hearing of the brain after 16 days of study;
  • ⁇ ig. 5 the diagram of the intensity of the inclusion of ⁇ -leucine in the enriched by the fractions of the case of taking the hearing of the brain from the results of a biochemical study;
  • ⁇ ig. 6 - a diagram of changes in the dynamics of death after exposure to the influence of the claimed neighbors obtained from the thymus and thymus + spleen;
  • ⁇ ig. 8 the sharp intensities of the inclusion of labeled thymidine in the cells of the testes after administration to the cereals of the claimed products obtained from the testes;
  • ⁇ ig. 10 rapid withdrawal of the thymidine label from the liver at a monthly, monthly, and six-month intervals after a partial section of the liver;
  • the claimed equipment may be incurred in small ways, which are described below.
  • the resulting upper phase which contains ⁇ , removes and removes 350 ml of a mixture of phenol and hydrogen from it at a ratio of 1: 1, warms and freezes.
  • ⁇ As a result of the last center of activity, four fractions are received.
  • the resulting product is in the form of a powder of 2% to 5% protein and more than 94.0% low molecular weight PP.
  • the main part of impurities is composed of high molecular weight ⁇ and ⁇ . Constants of 'sedimentation of separate components of the obtained products are in the range of values from 3.0 to 8 to 8,5.
  • the yield of the substance is 1.0 mg to 1.2 mg from 1 g of tissue.
  • the resulting product range is 2.9%> up to 4.2% protein and 90% up to 92% low molecular weight food.
  • the main part of impurities is ⁇ high molecular weight and ⁇ .
  • the average value of the sedimentation factor is in the range from 3.5 to 8 to 8. 8.
  • the sedimentation parameters of the individual fractions are available in the range of 3.0 to 8 to 8, and 8 are received. 6.5 8, which indicates the identity of this component with a device obtained from a core of an open source.
  • the brain is processed in accordance with the first version of the method for the production of cell-poison fractions.
  • Aliquit of the obtained nuclear material adds five percent of the volume, which is 6% guanidine, 5-room the disease
  • the nuclear material is homogenized at a speed of 4,000 minutes per minute for two minutes and add only 1 g of cesium to each 2.5 ml.
  • the yield of the substance is 100 to 210 mcg from 1 g of tissue.
  • the resulting product range is from 1.2% to 3.5% protein and from 94% to 96.5% low molecular weight protein.
  • the main part of impurities is composed of high molecular weight ⁇ and ⁇ . ⁇ ns ⁇ an ⁇ y sedimen ⁇ atsii ⁇ delny ⁇ ⁇ a ⁇ tsy na ⁇ dya ⁇ sya in ⁇ edela ⁇ values ⁇ 3,08 d ⁇ 6.58 and ⁇ sn ⁇ vn ⁇ e ⁇ liches ⁇ v ⁇ a ⁇ ivny ⁇ ⁇ a ⁇ tsy in ⁇ edela ⁇ ⁇ 4,08 d ⁇ 6.58 ch ⁇ u ⁇ azyvae ⁇ on iden ⁇ ichn ⁇ s ⁇ ⁇ luchenn ⁇ g ⁇ s ⁇ eds ⁇ va s ⁇ s ⁇ eds ⁇ vami, ⁇ luchennymi in s ⁇ ve ⁇ s ⁇ vii s ⁇ s ⁇ s ⁇ bami, above ⁇ isannymi .
  • EXAMPLE 1 The effect of the claimed mediation on the defeated neurons of the brain.
  • the first series of tests was 120 num- ber of upstream groups, females of the “Institute”, which were divided into six regular groups. Half of the speed was reduced to hypoxia, which was used as a factor, which damages the brain, and 11 the second half of the cross did not push the hypoxia.
  • the drug for injections was a product of 125 mcg of the claimed medication in 1 ml of physiological solution.
  • the claimed device was obtained from the main brain of a small business by means of a method described in the process.
  • the drug for injections contained 94% to 96.5%> low molecular weight, and the average value of sedimentation constant was equal to 3.08 to 6.58. Injections of the SAC and above the described preparation took another three times a day on the third, sixth and seventh day.
  • the remaining half of the rim of the analogous first half of the rim was halted by the injection of ⁇ -leucine after 162 days after hypoxia, and then the biochemistry was performed.
  • Fig. 1 and ⁇ ig. 2 The results of the study of fractions of enriched neurons are presented in Fig. 1 and ⁇ ig. 2, and the results of a study of fractions enriched in glia are presented in Fig. 3 and ⁇ ig. 4.
  • Diagrams presented on Fig. 1 and ⁇ ig. 3 corresponds to the results of studies presented after 42 days after hypoxia, and the diagrams in Fig. 2 and ⁇ ig. 4 is consistent with the results of studies of data obtained after 162 days after hypoxia.
  • Fig. 1, ⁇ ig. 2, ⁇ ig. 3 and ⁇ ig. 4 the following are used 12 notations: the scintillation counts were indicated, and the name was radiant with a pulse size of 0.0001mg of the studied fraction per minute.
  • Each column of the diagram corresponds to a specific group of the studied colors, and
  • the data of biochemical research showed that the effect of hypoxia leads to a decrease in the synthesis of protein in it during the previous period of life, and, in the first place, for the first eight days.
  • the experience was as follows: the casualty group, the males of the “System” weighing 300 grams to 340 grams were divided into five equal groups. The first eight times were delivered as part of the market, and all the rest were redirected to a single gamma exposure up to 700 degrees. The irradiation was carried out at a temperature of 20 ° ⁇ at the installation with a source of 137Cs (dose rate of 4.7 g / min). Seven of the irrelevant groups were irradiated for the second group, and live animals were notified of the irregularities. The treatment course included seven injections of the drug in the developed scheme.
  • the filter count was calculated on the basis of the ⁇ - 8- 6800 ⁇ type counter using a scintillator for a heterogeneous account.
  • the results of this experiment are presented in Table 1, where the inclusions of 3 ⁇ -thymitine and 3 ⁇ -leucine in the ⁇ ⁇ go system are indicated.
  • EXAMPLE 3 The influence of the claimed medication, obtained from immunocompetent tissues, in the case of quantitative lethal outcomes in animals, which has been achieved with gamma-ray accidents.
  • the claimed medium was used, isolated from the small intestine, the small brain, the thymus and the spleen of the gastrointestinal tract.
  • all the received equipment contained 2> up to 5%> protein and more than 94% low-molecular weight.
  • the main part of the impurities in the medium is ⁇ high molecular weight, as well as traces of ⁇ are identified.
  • the sedimentation constants of individual fractions were in the range of values from 3.08 to 6.58.
  • FIG. 6 The results of the first stage are shown in FIG. 6 in the form of a diagram, a change in the dynamics of death after exposure to the effect of the claimed substance, obtained from the thymus and thymus and spleen, is shown on a recent basis.
  • Diagram on ⁇ ig. 6 clearly demon- strates the ability to change the course of development of gamma-irradiation syndromes, while there is an incidence of immune-related illnesses.
  • the direct result of the thymus is that it has a positive effect on the number of patients in the group, which is also a significant improvement.
  • the addition of a thymus adjuvant from a spleen significantly enhances the therapeutic effect. In this way, this is an experiment in the demon- stration of the use of mixtures of substances isolated from various devices for the treatment of radiation sickness.
  • the first group in the table is indicated as “online”.
  • the “ ⁇ ” group but this group had received a daily injection of 750 mcg, had been received, but for three days before the exposure,
  • the living group similarly entered into a medication, only the result of a large brain.
  • the other groups of the Czech Republic were introduced after irradiation.
  • the SCC and the CCP4 introduced a medication obtained from a small intestine with a single injection during the course of the consecutive days.
  • the OMZ group UM12 entered into a medication obtained from a direct injection in the course of a respective course and twelve days after irradiation.
  • the group received a medication received from a direct injection after three days after exposure, then on the sixth, eighth and tenth days. In all cases, the dose of a deductible was 750 micrograms.
  • Table 2 provides for the separation of lethal outcomes at interest rates for a period of thirty days. The last line indicates the percentage of survivors.
  • the introduction of a means of administering a medium has made it possible to achieve more significant effects.
  • ⁇ ⁇ y ⁇ a ⁇ studied changes ⁇ n ⁇ sheniya ⁇ li ⁇ ma ⁇ ilny ⁇ e ⁇ i ⁇ tsi ⁇ v ( ⁇ e ⁇ i ⁇ ul ⁇ tsi ⁇ v) K n ⁇ malnym z ⁇ elym e ⁇ i ⁇ tsi ⁇ am (tsi ⁇ sichn ⁇ s ⁇ ) ⁇ e in n ⁇ me ⁇ iblizi ⁇ eln ⁇ ⁇ avn ⁇ unit and susches ⁇ venn ⁇ menyae ⁇ sya ⁇ i ⁇ azny ⁇ vneshni ⁇ v ⁇ zdeys ⁇ viya ⁇ , ⁇ al ⁇ th changes in ⁇ ine ⁇ i ⁇ e s ⁇ z ⁇ evaniya ⁇ le ⁇ .
  • Group I is a direct group that has not been exposed to radiation.
  • the other groups of mice were irradiated with gamma radiation at a dose of 4 Group, after which Group II did not enter the claimed mediation, and the other groups were notified of the missing accidents.
  • Group III was given medication in the dose of BMKG, group IV - in the dose of 45 mkg, group V - in the dose of 100 mkg and group VI - in the dose of 150 mkg.
  • ⁇ a 1000 issled ⁇ vanny ⁇ ⁇ e ⁇ i ⁇ ul ⁇ tsi ⁇ v in ⁇ n ⁇ le ⁇ egis ⁇ i ⁇ val ⁇ s ⁇ 2,4 d ⁇ 4.0 ⁇ le ⁇ with mi ⁇ yad ⁇ ami and ⁇ n ⁇ shenie ⁇ li ⁇ ma ⁇ ilny ⁇ e ⁇ i ⁇ tsi ⁇ v ( ⁇ e ⁇ i ⁇ ul ⁇ tsi ⁇ v) ⁇ n ⁇ malnym z ⁇ elym e ⁇ i ⁇ tsi ⁇ am (in ⁇ ablitse u ⁇ azan ⁇ ⁇ a ⁇ « ⁇ / E") ⁇ avnyal ⁇ s ⁇ 0,7 d ⁇ 0.8 .
  • Table 4 shows the results of the influence of the removal of black hats from the sixth channel (GCC) in combination with the effect of gamma radiation on the cell
  • EXAMPLE 4 Merger of the claimed device, obtained from the thyroid gland of the small quick-shoot, on the intensity of the general exchange and on the synthesis of traffic and 21 years ago.
  • the claimed device obtained from the thyroid gland of the large quick-disconnect, in accordance with the first variant of the system.
  • the resulting product was 2%> up to 5%> protein and over 94> the claimed product.
  • the main part of the impurities is ⁇ high molecular weight, traces of ⁇ are identified.
  • the sedimentation constants of individual fractions were in the range of values from 3.08 to 6.58.
  • the weight of the carts was from 400 to 475 grams. All animals were divided into five equal groups. The average weight of animals in the kalsdoy group was approximately 440 grams.
  • the whole living group and the IV group were administered with injections every other day, during the month the claimed mediocre, received from the shield, was easy to play; .
  • Live group IV was administered 3 times 2.5 mg with an interval of 8 hours.
  • the vibrant business group V introduced a physiological environment for the most part.
  • Handguns correspond to the average weight of six divisions.
  • the effect of the claimed medication from the thyroid gland is also reduced to some small beneficiaries with impaired lipid metabolism and excess weight.
  • Example 5 Bolnoy ⁇ . Weight 58 years, height 185 cm, weight 104 kg, pressure 110/180. The diagnosis is a gynecological disease, excess weight, and cardiopulmonary bypass. After 3 days, a large amount of 20 mg of the drug from the shin-like mild leukemia, which was 0.5%> non-novocaine, was administered more painfully. After completing the injection route daily for the next 15 days, we conducted an investigation 24 injection sites, rapid weighing and measuring of blood pressure. No acute reactions at the site of injection were found for any of the reactions that occurred at the site of injection. On the 5th day (a day after the last injection), the mass of the patient decreased to 91 kg, the pressure decreased to 90/140. In the following 15 days, the mass and pressure of the boldest changes slightly to the extent of the usual daily rate.
  • ⁇ a ⁇ im ⁇ b ⁇ az ⁇ m in ⁇ ezul ⁇ a ⁇ e ⁇ bn ⁇ y ⁇ ve ⁇ i e ⁇ e ⁇ ivn ⁇ s ⁇ i is ⁇ lz ⁇ vaniya zayavlyaem ⁇ g ⁇ s ⁇ eds ⁇ va of schi ⁇ vidn ⁇ y gland mle ⁇ i ⁇ ayuschi ⁇ on b ⁇ lny ⁇ with izby ⁇ chn ⁇ y mass ⁇ y was ⁇ azan s ⁇ y ⁇ y ⁇ l ⁇ zhi ⁇ elny e ⁇ e ⁇ ⁇ nizheniya mass ⁇ ela and n ⁇ malizatsiya bi ⁇ sin ⁇ eza g ⁇ m ⁇ n ⁇ v ( ⁇ iy ⁇ d ⁇ i ⁇ nina and ⁇ i ⁇ sina) in ⁇ vi ⁇ sle ⁇ e ⁇ a ⁇ ny ⁇ and ⁇ ya ⁇ i ⁇ a ⁇ ny ⁇ vnu ⁇ imyshechny ⁇ ine ⁇ tsy.
  • P ⁇ ivedennye issled ⁇ vaniya u ⁇ azshayu ⁇ on ⁇ intsi ⁇ ialnuyu v ⁇ zm ⁇ zhn ⁇ s ⁇ is ⁇ lz ⁇ vaniya s ⁇ eds ⁇ va of schi ⁇ vidn ⁇ y gland ⁇ liniches ⁇ y ⁇ a ⁇ i ⁇ e and ⁇ e ⁇ s ⁇ e ⁇ ivn ⁇ s ⁇ dalneyshi ⁇ issled ⁇ vany the purpose ⁇ az ⁇ ab ⁇ i ⁇ e ⁇ a ⁇ a ⁇ v, s ⁇ s ⁇ bny ⁇ ⁇ e ⁇ i ⁇ va ⁇ u ⁇ ven ⁇ bmena, g ⁇ m ⁇ naln ⁇ g ⁇ s ⁇ a ⁇ usa, weight reduction and n ⁇ malizatsii ⁇ ela mle ⁇ i ⁇ ayuschi ⁇ and chel ⁇ ve ⁇ a.
  • Example 6 The influence of the claimed medication, obtained from the testes of young bulls, into the division of the cell of the epidermal epithelium (the reactive synthesis of D).
  • the medications started to enter 14C-IISIDI (64 micros per 1 kg of weight, specific 69 ml / m) for 1 ml of a chemical mixture of 8. After 8 hours after the administration of thymidine, all live parts were taken.
  • Tests were isolated from animals, they were fixed in a mixture of 10> raspberries, and they were removed from them at a temperature of approximately 20 mg, in addition to 200 mg, apart from them, Za ⁇ em ⁇ bi ⁇ i vsche ⁇ lshvali in ⁇ e ⁇ m ⁇ s ⁇ a ⁇ e ⁇ i ⁇ em ⁇ e ⁇ a ⁇ u ⁇ e 60 ° C d ⁇ ⁇ ln ⁇ g ⁇ ⁇ as ⁇ v ⁇ eniya ⁇ ani, d ⁇ bavlyali ⁇ 5ml zhid ⁇ s ⁇ n ⁇ g ⁇ ⁇ lu ⁇ ln ⁇ g ⁇ stsin ⁇ illya ⁇ a and ⁇ schi ⁇ tali on zhid ⁇ s ⁇ n ⁇ m stsin ⁇ ildyatsi ⁇ nn ⁇ m sche ⁇ chi ⁇ e, ⁇ edelyaya ⁇ t values.
  • the claimed device obtained from the brain, behaves in a completely different way in this experiment (in Fig. 9, I turn around - I turn around, I turn around II - turn). For him 26 terno only nonspecific stimulation of the D synthesis in the testes up to six days. Then, the level of polishing of the cells is in good condition and remains the same even further.
  • Example 7 Study of the effect of the claimed device on the genetic effect of gamma irradiation in mice and on genetic injuries in human cells.
  • the claimed device which was integrated from the products of a large quick-release system in accordance with the second variant of the system.
  • the resulting product range is 2.9%> up to 4.2%> protein and 90%> up to 92% low molecular weight food.
  • the main part of impurities is ⁇ high molecular weight. Traces of F are identified.
  • the average value of sedimentation constant is from 3.58 to 6.58.
  • the sedimentation indicators of individual fractions were in the range of values from 3.08 to 6.58, and the main active fractions in the range of 3.58 to 6.58.
  • the irradiation was carried out on a gamma installation with a radiation source of 137 Cs, dose rate of 6.12 G / min.
  • the claimed medicament was administered to the homeless in physiological growth of 0.2 ml in doses of 4, 10 and 20 mg per kilogram of the weight of a single product or a large number of cases.
  • the genetic indicators were also studied for male mice at the advantage of effective cramping and the change in the mass of the testes, which affects the cyclic rate.
  • the frequency of occurrences of abnormal spearmy heads was analyzed on 27 airborne dry strokes, derived from environmental epididyms of irradiated live animals. Every male counted at least 300 serpmes. After the males had forgotten, after 35 and 45 days after the expiration of the exposure, the body mass and the testes mass were divided.
  • mice of the ⁇ - ⁇ line we found a decrease in the frequency of abnormal head achemias in mice of the ⁇ - ⁇ line in a similar variant of the experiment. It was found that there were similar variants of the experiment (3 G + five injections of Yumg / kg of the claimed substance) on mice that have different genes: gray hybrids, white mice. The therapeutic effect in the highest degree was observed in linear mice. Advantageous effect in hybrid mice was found only in experiments on old mice. This allows you to take advantage of the proclamation of the claimed device in connection with the stimulation of the free-to-use system of mice and tones. In general, the beneficial effect is most pronounced in the presence of a relatively high dose of radiation and the introduction of the declared product after the introduction.
  • Example 8 The influence of the claimed medication obtained from the body of the substance, and the claimed mediation obtained from the case of overbooks of financial risk.
  • the claimed device used the claimed device, isolated from the adverts of the direct access to the quick variant of the method.
  • the resulting average share was 2.9%> up to 4.2% protein and 90% up to 92% low molecular weight food.
  • the main part of the impurities was ⁇ high molecular weight. Traces of ⁇ were identified.
  • the sedimentation indicators of individual fractions were in the range of values from 3.08 to 6.58, and the main active fractions in the range of 3.58 to 6.58.
  • the second series of the ex- periment used the claimed medication isolated from the acute layer of the urine in the dose of 0, 1 mg / kg and 1 mg / kg, because The use of the claimed mediocre from the main brain was taken as a part of the panel for identifying the specifics of the resulting effects. ⁇ ezul ⁇ a ⁇ y e ⁇ s ⁇ e ⁇ imen ⁇ v ⁇ eds ⁇ avleny in ⁇ ablitse 9.
  • Example 9 The division of the battery life ( ⁇ / 2) and the change in this indicator in old deaths when introducing the claimed device.
  • Vibrant groups were distinguished by that, that it daily for 10 days before the start of the test on cleaned body parts were consumed in the gel (10 mg were consumed at a rate of 100 mg. 4 cm 2 skin, while live animals received gel without any medication.
  • ⁇ a ⁇ ig. 12 first transistors and diagrams indicate the inclusion in ⁇ 3 of ⁇ -thymidine per unit mass of each of the other traces of the studied age groups: 2, 10 32 and 20 months. Be sure to note a wise reduction in the synthesis of D with old animals. These results are fully agreed with the majority of studies of the industrial parameters of the D synthesis in leather and cell cords of its separate layers. ⁇ zdeys ⁇ vie on ⁇ zhu zhiv ⁇ ny ⁇ as claimed s ⁇ eds ⁇ v ⁇ m a ⁇ li ⁇ atsy (on ⁇ ig.
  • live animals were injected with nectin and amino acids and separate fractions of collagen and elastin were isolated from the dermis. All of these procedures were then duplicated in experiments in the ⁇ ⁇ ⁇ system for the preparation of leather from the same animals, studying the inclusion of 14 C-amino acids. Livestock groups were distinguished by that, as well as by them, and in the previous experience, every day for 10 days before starting to eat, they consume 10 percent to eat. Factory 940 ⁇ 8.0) Dose 200mg per 4 cm 2 skin, while the live group received gel without immediate effect.
  • ⁇ ezul ⁇ a ⁇ y study v ⁇ lyucheniya me ⁇ i per unit mass ⁇ a ⁇ tsy ⁇ llagena ⁇ eds ⁇ avleny in ⁇ ablitse 10.
  • ⁇ ⁇ ablitse is ⁇ lz ⁇ vany ⁇ b ⁇ znacheniya following: ⁇ - s ⁇ le ⁇ as ⁇ v ⁇ imaya ⁇ a ⁇ tsiya ⁇ llagena, ⁇ 2 - ⁇ a ⁇ tsiya ⁇ llagena, ⁇ as ⁇ v ⁇ imaya in ⁇ isl ⁇ m atse ⁇ a ⁇ n ⁇ m bu ⁇ e ⁇ e, ⁇ 3 - ne ⁇ as ⁇ v ⁇ imy ⁇ llagen, ⁇ - ⁇ y ⁇ ⁇ ⁇ v ⁇ lyuchenie 3 ⁇ -amino acids and 14 C - experience ⁇ in all cases including 14 C-amino acids.
  • Example 11 Evaluation of the effectiveness of the use of the claimed medication in a large herbal infection caused by a viral herpes virus.
  • the basic treatment for volunteers was the recurrent course of the disease, with a frequency of recurrence of at least 1 time in 6 months.
  • the medications received from different organisms and tissues are used. Immediately, a dose of 5-10 mg was applied, for one day, two days.
  • the product is equipped with a generic herbal mixture, but it had a generous content instead of a gray one.
  • the skin-friendly process after application of the medication was done as usual, without obvious acceleration, with the occurrence of relapses with the same treatment, as well.
  • New relapses were softer, with weakly expressed sensations of burning, pricking, soreness.
  • hyperemia hyperemia
  • easy flow treatment was lost for a period of three weeks.
  • single, very small erosions appeared, which were manifested by point-like serous circles. The process resolved at the end of the fourth week of observation. New relapses appeared with the same regularity, both for treatment and for treatment, but, as a result of a great illness, they flowed softer.
  • Example 12 Evaluation of the effectiveness of the use of the claimed medication in normalizing the level of transaminases in patients with poor hepatitis C and C.
  • the patient received intensive therapy including high doses of vitamins, antibiotics, and an interval of 40,000 days a day for 7 days, one day for one day.
  • intensive therapy including high doses of vitamins, antibiotics, and an interval of 40,000 days a day for 7 days, one day for one day.
  • ⁇ a v ⁇ ye su ⁇ i ⁇ m ⁇ men ⁇ a introduction ⁇ e ⁇ a ⁇ a ⁇ a ⁇ mechal ⁇ s ⁇ ez ⁇ e improvement
  • ⁇ bscheg ⁇ s ⁇ s ⁇ yaniya b ⁇ lny ⁇ have ⁇ b ⁇ i ⁇ b ⁇ lny ⁇ on ⁇ e ⁇ i su ⁇ i ⁇ mechen ⁇ znachi ⁇ eln ⁇ e reduction ⁇ e ⁇ a and gi ⁇ e ⁇ emii in ⁇ chaga ⁇ ⁇ azheniya, vysy ⁇ aniya ⁇ ds ⁇ li, ⁇ ylis ⁇ ch ⁇ ami, while b ⁇ ln ⁇ y ⁇ e ⁇ a ⁇ ilsya b ⁇ lev ⁇ y Sind ⁇ m.
  • the lesion foci had a persistent cyanotic color with persistent erosion in the area, eruptive in general. Fifty-eight foci make up a bluish color, and in a large place at the site of large erosion, a formation of teeth is noted.
  • EXAMPLE 14 Evaluation of the effectiveness of the use of the claimed medication in the treatment of papillomuscular infections.
  • this unit By accessing this unit from the outside in excess of quantity, it stimulates the operation of all normal functioning links and inactivates the work of the rooms. Such a section is independent of the cause, which caused this disturbance and leads to the correction of all links of the external chain of the lower to the highest.
  • ch ⁇ for it is ⁇ lzuyu ⁇ sya s ⁇ edineniya, ⁇ ye ⁇ ab ⁇ ayu ⁇ in ⁇ e ⁇ same ⁇ le ⁇ a ⁇ in n ⁇ me, s ⁇ ve ⁇ shenn ⁇ bezv ⁇ edny for ⁇ ganizma and ne ⁇ ne ⁇ b ⁇ dim ⁇ s ⁇ i in sin ⁇ e ⁇ iches ⁇ i ⁇ s ⁇ edineniya ⁇ , sl ⁇ zhny ⁇ e ⁇ s ⁇ a ⁇ a ⁇ of ⁇ as ⁇ eny and d ⁇ ugi ⁇ ⁇ d ⁇ bny ⁇ vesches ⁇ v.
  • ⁇ se e ⁇ dae ⁇ ⁇ sn ⁇ vaniya schi ⁇ a ⁇ is ⁇ lz ⁇ vanie e ⁇ z ⁇ genny ⁇ ⁇ egulya ⁇ v ⁇ izi ⁇ l ⁇ giches ⁇ g ⁇ s ⁇ s ⁇ yaniya ⁇ le ⁇ , ⁇ aney and ⁇ gan ⁇ v n ⁇ vym very ⁇ e ⁇ s ⁇ e ⁇ ivnym ⁇ d ⁇ d ⁇ m ⁇ ⁇ e ⁇ tsii ⁇ bmena and treatment ⁇ a ⁇ l ⁇ gy in ⁇ m including the u ⁇ vne gen ⁇ ma and themselves ⁇ P ⁇ assma ⁇ iva ⁇ ⁇ a ⁇ ⁇ din of n ⁇ vy ⁇ , e ⁇ e ⁇ ivny ⁇ ⁇ lass ⁇ v bi ⁇ l ⁇ giches ⁇ i a ⁇ ivny ⁇ vesches ⁇ v and Regulators used in genetic therapy.
  • the inventive component may be used in studies of tissue diffraction and dedifferentiation, biosynthesis, replication, and transient use. 40 experimental and therapeutic veterinary medicine and for the purposeful and specialized treatment in medical business.
  • ⁇ as ⁇ edelenie le ⁇ alny ⁇ is ⁇ d ⁇ v ⁇ days at 30 ⁇ e ⁇ vye su ⁇ ⁇ sle ⁇ dn ⁇ a ⁇ n ⁇ g ⁇ gamma ⁇ blucheniya ⁇ ys in d ⁇ ze 700 ⁇ ad and introducing them from s ⁇ eds ⁇ va ⁇ n ⁇ g ⁇ ⁇ ishechni ⁇ a ( ⁇ ) or ⁇ s ⁇ n ⁇ g ⁇ m ⁇ zga ( ⁇ ) ⁇ 750 m ⁇ g in u ⁇ azannye s ⁇ el ⁇ ami d ⁇ days and ⁇ sle ⁇ blucheniya. Each square means 10% dead or survivors. 43
  • ⁇ I is the value of the phylactic index.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à la médecine et à la chimie biologique, à la cytologie, à la biologie moléculaire et à la génétique. Elle concerne plus précisément des produits pour normaliser la structure et les fonctions d'organes et de tissus, pour stimuler la réparation de lésions, et qui ont une activité antivirale. Le produit de l'invention se présente comme un ensemble de fractions de ribonucléoprotéine présentant une constante de sédimentation comprise entre 3 S et 6,5 S, ce qui correspond exactement aux paramètres moyens des masses moléculaires de la classe des ribonucléoprotéines nucléaires à faible poids moléculaire. La teneur globale des acides nucléiques dans le produit de l'invention est de 90 % en poids ou plus, et des protéines entre 0,5 et 5,0 % en poids, le reste étant constitué d'impuretés d'ADN et d'ARN à poids moléculaire élevé, et ce jusqu'à 100 % en poids. Le produit de l'invention peut s'utiliser dans les recherches portant sur la différenciation et la dédifférenciation de tissus, la biosynthèse, la réplication et la transcription lors de l'application de différents effets fonctionnels sur le corps humain, en médecine vétérinaire expérimentale et curative, en cosmétique et à des fins de recherche ciblée dans le domaine médical.
PCT/EA2004/000001 2003-01-24 2004-01-26 Produit normalisant la structure et les fonctions des organes et tissus, stimulant les reparations des lesions et possedant une activite antivirale WO2004064849A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2003101855A RU2238756C1 (ru) 2003-01-24 2003-01-24 Средство, стимулирующее репарирование повреждений, обладающее ткане-, органо- и стадиеспецифичностью и противовирусной активностью
RU2003101855 2003-01-24

Publications (1)

Publication Number Publication Date
WO2004064849A1 true WO2004064849A1 (fr) 2004-08-05

Family

ID=32768746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EA2004/000001 WO2004064849A1 (fr) 2003-01-24 2004-01-26 Produit normalisant la structure et les fonctions des organes et tissus, stimulant les reparations des lesions et possedant une activite antivirale

Country Status (2)

Country Link
RU (1) RU2238756C1 (fr)
WO (1) WO2004064849A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2620069C2 (ru) 2014-06-26 2017-05-22 Аоварт Гмбх Вещество и способ модуляции пролиферации и дифференцировки регуляторных, стволовых и других соматических клеток
RU2624504C1 (ru) * 2015-12-30 2017-07-04 Маргарита Евгеньевна Дмитриева Способ получения трансфер-фактора для профилактики вирусных болезней птиц
RU2766083C1 (ru) * 2020-11-26 2022-02-07 Михаил Сергеевич Краснов Биологически активная субстанция в виде биорегуляторной композиции, обладающая поддерживающим и восстановительным действием на ткани и органы, и фармакологическая композиция

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2144366C1 (ru) * 1998-03-03 2000-01-20 Закрытое акционерное общество "Астера" Средство, стимулирующее рост волос, и способ его получения

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2144366C1 (ru) * 1998-03-03 2000-01-20 Закрытое акционерное общество "Астера" Средство, стимулирующее рост волос, и способ его получения

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JIAN GU ET AL.: "Small RNA database", NUCLEIC ACID RESEARCH, vol. 25, no. 1, 1997, pages 98 - 101 *
KONSTANTINOVA I.M.: "Malye tsitoplazmaticheskie RNP v kletochnykh protsessakh", TSITOLOGIYA, no. 2, 1996, pages 211 - 212, Retrieved from the Internet <URL:http://compag.viniti.Ru/cgi-win/webirbis.exe> *
MAZIN A.L.: "Nizkomolekulyarnye RNK eukariot:biogenez, subkletochnaya lokalizatsiya, funktsii", MOLEKULYARNAYA BIOLOGIYA, vol. 17, no. 4, 1983, pages 762 - 763,766-769 *

Also Published As

Publication number Publication date
RU2238756C1 (ru) 2004-10-27

Similar Documents

Publication Publication Date Title
WO2005004903A1 (fr) Methode de traitement de maladies oncologiques
CN110724203B (zh) 一种促进tfeb核转位的短肽及基于其的线性短肽和其减轻脑缺血损伤的应用
WO1984002470A1 (fr) Preparation medicinale pour le traitement therapeutique d&#39;ulceres peptiques
WO1990012584A1 (fr) Preparation ayant un action anti-inflammatoire, lactogene et stimulante, et procede pour sa fabrication
EA000885B1 (ru) Лекарственное средство и способ медикаментозного воздействия на организм
WO1995022336A1 (fr) Agent immunomodulateur et reducteur du dysfonctionnement du systeme de regulation de la propagation de cellules tissulaires
WO2005007187A1 (fr) Methode de traitement des maladies oncologiques, infectieuses et somatiques, procedes de controle de l&#39;efficacite du traitement, agents et compositions pharmaceutiques associes
WO1994001099A1 (fr) Composition pharmaceutique presentant des actions anti-alcool stimulant le metabolisme de l&#39;energie, stimulant les fonctions de production et de secretion d&#39;acide de la membrane muqueuse de l&#39;estomac, et presentant egalement des actions radioprotectrice et anti-cholera
WO2003040723A1 (fr) Procede de rehabilitation de l&#39;organisme en cas d&#39;infection virale lente
BRODIE et al. Acute hepatic porphyrias
WO2004064849A1 (fr) Produit normalisant la structure et les fonctions des organes et tissus, stimulant les reparations des lesions et possedant une activite antivirale
WO1994028153A2 (fr) Adn de faible masse moleculaire tiree de laitance d&#39;esturgeon, procede d&#39;obtention de l&#39;adn et preparation pharmaceutique a base de celui-ci
WO2004043485A1 (fr) Composition presentant des proprietes antioxydantes, procede de production d&#39;un polypeptide et methode de traitement
EP0348507A4 (en) Pharmaceutical preparation for individual prophylaxis of venereal diseases and curing urogenital trichomoniasis
WO2005004789A2 (fr) Methode de traitement de maladies s&#39;accompagnant d&#39;alterations de la composition qualitative ou quantitative de l&#39;adn extracellulaire du sang
WO2005004904A1 (fr) Methode de traitement de maladies s&#39;accompagnant d&#39;alterations de la composition qualitative et/ou quantitative de l&#39;adn extracellulaire du sang (variantes)
WO2002080938A1 (fr) Application de nucleospermate de sodium pour traiter le sida et procede de traitement
US20100029590A1 (en) Methods for treating or preventing hemorrhagic cystitis using a glycerophosphate salt
WO1997037651A1 (fr) Procede de preparation d&#39;un medicament (trecresan) ayant une action nootrope
RU2415668C2 (ru) Способ лечения и профилактики отравлений фосфорорганическими инсектицидами (фои)
WO1997045530A1 (fr) Utilisation de souches de streptococcus faecium et composition a base de ces souches
RU2395278C1 (ru) Способ получения комплексного препарата для профилактики и лечения патологий обмена веществ и нарушений функций иммунной системы животных
WO2005021007A1 (fr) Prevention et traitement de l&#39;hepatite virale b
WO2001012201A1 (fr) Composition remplacant le plasma sanguin
RU2321393C1 (ru) Способ лечения телят, больных неспецифической катаральной бронхопневмонией

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase